4//SEC Filing
Canaan XI L.P. 4
Accession 0000899243-22-031602
CIK 0001845337other
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 5:47 PM ET
Size
15.9 KB
Accession
0000899243-22-031602
Insider Transaction Report
Form 4
Canaan XI L.P.
10% Owner
Transactions
- Sale
Common Stock
2022-09-20$19.50/sh−146,404$2,854,878→ 9,080,170 total - Sale
Common Stock
2022-09-16$21.53/sh−111,585$2,402,425→ 9,307,021 total - Sale
Common Stock
2022-09-16$22.04/sh−3,722$82,033→ 9,303,299 total - Sale
Common Stock
2022-09-19$20.57/sh−76,725$1,578,233→ 9,226,574 total - Sale
Common Stock
2022-09-20$20.10/sh−2,266$45,547→ 9,077,904 total
Canaan Partners XI LLC
10% Owner
Transactions
- Sale
Common Stock
2022-09-16$21.53/sh−111,585$2,402,425→ 9,307,021 total - Sale
Common Stock
2022-09-16$22.04/sh−3,722$82,033→ 9,303,299 total - Sale
Common Stock
2022-09-20$20.10/sh−2,266$45,547→ 9,077,904 total - Sale
Common Stock
2022-09-19$20.57/sh−76,725$1,578,233→ 9,226,574 total - Sale
Common Stock
2022-09-20$19.50/sh−146,404$2,854,878→ 9,080,170 total
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.98 - $21.97, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). Canaan Partners XI LLC ("Canaan XI") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.98 - $22.28, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.22 - $21.07, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.06 - $19.85, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.06 - $20.15, inclusive. The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Day One Biopharmaceuticals, Inc.
CIK 0001845337
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001712417
Filing Metadata
- Form type
- 4
- Filed
- Sep 19, 8:00 PM ET
- Accepted
- Sep 20, 5:47 PM ET
- Size
- 15.9 KB